Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.

Publication Type:

Journal Article

Authors:

Walter, Roland B; Kantarjian, Hagop M; Huang, Xuelin; Pierce, Sherry A; Sun, Zhuoxin; Gundacker, Holly M; Ravandi, Farhad; Faderl, Stefan H; Tallman, Martin S; Appelbaum, Frederick R; Estey, Elihu H

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 10, p.1766-71 (2010)

Keywords:

2010, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Center-Authored Paper, Clinical Research Division, Clinical Trials as Topic, Disease-Free Survival, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Prognosis, Remission Induction, Retrospective Studies, Time Factors, Treatment Outcome

Abstract:

It is known that complete remission (CR) prolongs survival in acute myeloid leukemia (AML). In 2003, less stringent response categories were introduced, most notably CR with incomplete platelet recovery (CRp). Although the significance of CRp for survival remains unclear, reports of AML trials frequently combine CR with CRp rather than considering CR as a separate entity.